Can Sunharbo become Bayer’s next cardiovascular blockbuster after Xarelto?
FDA approves Bayer’s Sunharbo after asundexian cut recurrent ischemic stroke risk 26% without significantly increasing major bleeding.
Pharma & Biotech
Pharma & Biotech
Bayer’s LYNKUET cut poor sleep reports sharply, but does that make it a menopause sleep treatment?
Bayer's LYNKUET showed improved self-reported sleep quality in a post-hoc Phase 3 analysis. The findings do not establish a separate sleep indication.
Pharma & Biotech
Bayer reports 58% lower metastasis or death risk with NUBEQA in Phase 3 prostate cancer trial
Bayer's NUBEQA improved four-year metastasis-free survival to 95% in high-risk prostate cancer. Overall survival evidence remains immature.
Pharma & Biotech
One ABCL635 injection cut hot flashes by 83%. Can AbCellera prove the benefit lasts?
AbCellera will reveal new ABCL635 safety and symptom data after reporting an 83% hot flash reduction. Can its antibody sustain the benefit?
Pharma & Biotech
Roche wins EU approval for Susvimo as wet AMD treatment burden becomes the next battleground
The European Commission has approved Roche’s Susvimo implant for neovascular age-related macular degeneration, offering continuous ranibizumab delivery with refills every six months and creating a fundamentally different alternative to repeated eye injections.
Features & Analysis
HYRNUO reached untreated HER2-mutant NSCLC before its Phase 3 answer. What does Bayer need to prove next?
The FDA has expanded HYRNUO into first-line advanced HER2-mutated non-small cell lung cancer after a 75% response rate in an early-phase cohort. The approval gives Bayer an important head start, but rival oral therapies and unfinished confirmatory trials mean the long-term treatment hierarchy remains unsettled.
Pharma & Biotech
Is PMS relief becoming a consumer wellness category? Bayer’s Midol in Motion campaign suggests so
PMS relief is moving beyond pain pills. Bayer’s Midol campaign ties symptom care to movement, creators, and menstrual wellness.
Pharma & Biotech
NUBEQA data at AUA 2026 sharpens Bayer’s mCSPC positioning against androgen receptor rivals
Bayer has stronger NUBEQA mCSPC data. The tougher test is whether clinicians view ARASEC as confirmatory or merely supportive.
Medical Devices & Diagnostics
What Bayer’s MRXperion 510(k) clearance means for high-field MRI workflow and contrast injection systems
FDA clears expanded capabilities for Bayer MRXperion MRI injector supporting scanners up to 7T. Discover what this means for imaging workflows and radiology systems.
Pharma & Biotech
Real-world data meets legal limits as Bayer targets ERLEADA claims in prostate cancer
Bayer’s lawsuit against Johnson and Johnson raises critical questions about real-world evidence and oncology marketing. Read what this means for drug claims.